These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 7500770

  • 1. NSAIDs, Cox-2 inhibitors, and the gut.
    Hayllar J, Bjarnason I.
    Lancet; 1995 Dec 16; 346(8990):1629. PubMed ID: 7500770
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
    van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ.
    Br J Clin Pharmacol; 2002 Jun 16; 53(6):644-7. PubMed ID: 12047490
    [Abstract] [Full Text] [Related]

  • 3. NSAIDs, Cox-2 inhibitors, and the gut.
    Hayllar J, Bjarnason I.
    Lancet; 1995 Aug 26; 346(8974):521-2. PubMed ID: 7658776
    [No Abstract] [Full Text] [Related]

  • 4. Innovative treatment approaches for rheumatoid arthritis. New cyclo-oxygenase and cytokine inhibitors.
    Richardson CE, Emery P.
    Baillieres Clin Rheumatol; 1995 Nov 26; 9(4):731-58. PubMed ID: 8591651
    [Abstract] [Full Text] [Related]

  • 5. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance.
    Prieto A, De Barrio M, Martín E, Fernández-Bohórquez M, de Castro FJ, Ruiz FJ, Herrero T, Tornero P, Rubio M.
    J Allergy Clin Immunol; 2007 Apr 26; 119(4):960-4. PubMed ID: 17292954
    [Abstract] [Full Text] [Related]

  • 6. Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam.
    Curtiss FR.
    J Manag Care Pharm; 2006 Apr 26; 12(3):265-8. PubMed ID: 16623613
    [No Abstract] [Full Text] [Related]

  • 7. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings.
    Engelhardt G, Bögel R, Schnitzer C, Utzmann R.
    Biochem Pharmacol; 1996 Jan 12; 51(1):21-8. PubMed ID: 8534264
    [Abstract] [Full Text] [Related]

  • 8. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.
    Engelhardt G.
    Br J Rheumatol; 1996 Apr 12; 35 Suppl 1():4-12. PubMed ID: 8630636
    [Abstract] [Full Text] [Related]

  • 9. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.
    Giuliano F, Ferraz JG, Pereira R, de Nucci G, Warner TD.
    Eur J Pharmacol; 2001 Aug 24; 426(1-2):95-103. PubMed ID: 11525777
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
    Ogino K, Hatanaka K, Kawamura M, Katori M, Harada Y.
    Pharmacology; 1997 Jul 24; 55(1):44-53. PubMed ID: 9309800
    [Abstract] [Full Text] [Related]

  • 11. [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs].
    Poulsen Nautrup B, Hörstermann D.
    Dtsch Tierarztl Wochenschr; 1999 Mar 24; 106(3):94-100. PubMed ID: 10220944
    [Abstract] [Full Text] [Related]

  • 12. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.
    Beretta C, Garavaglia G, Cavalli M.
    Pharmacol Res; 2005 Oct 24; 52(4):302-6. PubMed ID: 15939622
    [Abstract] [Full Text] [Related]

  • 13. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Rainsford KD.
    Am J Med; 1999 Dec 13; 107(6A):27S-35S; discussion 35S-36S. PubMed ID: 10628591
    [Abstract] [Full Text] [Related]

  • 14. Rationalizing cyclooxygenase inhibition for optimization of efficacy and safety profiles. Proceedings of a workshop. Fort Worth, Texas, USA. February 1999.
    Am J Med; 1999 Dec 13; 107(6A):1S-89S. PubMed ID: 10628587
    [No Abstract] [Full Text] [Related]

  • 15. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
    Ogino K, Hatanaka K, Kawamura M, Ohno T, Harada Y.
    Pharmacology; 2000 Nov 13; 61(4):244-50. PubMed ID: 11093076
    [Abstract] [Full Text] [Related]

  • 16. [Meloxicam].
    Sternon J, Appelboom T.
    Rev Med Brux; 1998 Feb 13; 19(1):29-32. PubMed ID: 9553452
    [Abstract] [Full Text] [Related]

  • 17. Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.
    Smith HS, Baird W.
    Am J Hosp Palliat Care; 2003 Feb 13; 20(4):297-306. PubMed ID: 12911075
    [Abstract] [Full Text] [Related]

  • 18. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers.
    Patoia L, Santucci L, Furno P, Dionisi MS, Dell'Orso S, Romagnoli M, Sattarinia A, Marini MG.
    Br J Rheumatol; 1996 Apr 13; 35 Suppl 1():61-7. PubMed ID: 8630640
    [Abstract] [Full Text] [Related]

  • 19. [Pharma-Clinics. The drug of the month. Meloxicam (Mobic)].
    Scheen AJ.
    Rev Med Liege; 1997 Apr 13; 52(4):309-11. PubMed ID: 9273628
    [No Abstract] [Full Text] [Related]

  • 20. Tocolytic effect of the cyclooxygenase-2 inhibitor, meloxicam: studies on uterine contractions in the rat.
    Yousif MH, Thulesius O.
    J Pharm Pharmacol; 1998 Jun 13; 50(6):681-5. PubMed ID: 9680081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.